Harrow announced in a press release that it has entered into a definitive agreement to acquire Tyrvaya (varenicline solution) nasal spray 0.03 mg from Viatris Inc. Tyrvaya is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease (DED) and is currently approved in the United States, China, and Taiwan, with marketing authorization applications pending in other countries.

According to Harrow, the acquisition expands the company's dry eye portfolio, and complements its flagship Vevye franchise by addressing DED with a different underlying mechanism of action. Together, Harrow said Vevye and Tyrvaya provide physicians with a broader range of differentiated treatment options while addressing the diverse needs of patients with DED.

Because Tyrvaya is delivered as a nasal spray rather than an eye drop, it avoids ocular instillation-site reactions entirely; its prescribing information includes no contraindications and no warnings or precautions, and its most common adverse reaction—sneezing—is transient.

Harrow said the acquisition also leverages the company's sales, marketing, market access, medical affairs, and reimbursement infrastructure and is expected to further strengthen the company through the addition of select talent from Viatris.

Under the terms of the agreement, Harrow will pay $30 million in cash at closing and up to $70 million in contingent milestone payments tied to Tyrvaya's net sales, for a potential total consideration of up to $100 million. Harrow said it expects to fund the upfront cash payment using cash on hand. The transaction is expected to close in the second half of 2026, subject to customary closing conditions.